e-Drug3D

1507

GABAPENTIN ENACARBIL

INN
GABAPENTIN ENACARBIL

cas 478296-72-9

CLASS

NERVOUS SYSTEM
MODERATE-TO-SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) IN ADULTS
ANTIEPILEPTIC
POSTHERPETIC NEURALGIA (PHN)
GABAB AGONIST

ROUTE (list)

ORAL

ATC code

N02BF01

PK parameters

Solubility

0.5 MILLIGRAM / MILLILITER

Target

TARGET VOLTAGE-GATED CALCIUM CHANNEL (PMID26680202)

DrugCentral

Voltage-dependent calcium channel subunit alpha-2,delta-1 UNIPROT P54289 CACNA2D1

Voltage-dependent calcium channel subunit alpha-2,delta-2 UNIPROT Q9NY47 CACNA2D2

Download SDF file

Cyclohexaneacetic acid, 1-[[[[1-(2-methyl-1-oxopropoxy)ethoxy]carbonyl]amino]methyl]-

Formula:
C16H27NO6

Calculated chemical properties:

MW 328.38
NB_atoms 23
XLogP 1.35
PSA 90.227
NB_HD 1
NB_HA 7
fsp3 0.81
Lipinski(0=no;1=yes) 1

FDA
NDA 022399 (label) INN (GABAPENTIN ENACARBIL) HORIZANT (AZURITY) APPROVAL= AP YEAR= 2011 NEWMOLECULARENTITY
NDA 213501 (pdf not found) INN (GABAPENTIN ENACARBIL) GABAPENTIN ENCARBIL (GLENMARK PHARMS LTD) APPROVAL= TA YEAR= 2020